Search

Your search keyword '"Cuffe, Sinead"' showing total 21 results
Start Over Author "Cuffe, Sinead" Publication Year Range Last 3 years
21 results on '"Cuffe, Sinead"'

1. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Afanasyev, Sergey, Ahmed, Samreen, Alekshun, Todd, Alves, Gustavo, Anderson, Ian, Araujo, Luiz Henrique, Arkhipov, Alexander, Arora, Arvind, Bai, Jie, Begin, Paul, Belonogov, Aleksandr, Berard, Henri, Berceanu-Ion, Radu, Bernabe Caro, Reyes, Bondarenko, Igor, Bonnet, Reiner, Bosch Barrera, Joaquim, Brocca, Carlos, Bryl, Maciej, Bulotta, Alessandra, Bylicki, Olivier, Calles Blanco, Antonio, Carcereny, Enric, Carvalho, Leticia, Cebotaru, Cristina, Chaft, Jamie, Charu, Veena, Chaves, Fabio, Chen, Jun, Chen, Ke-Neng, Chen, Haiquan, Chen, Qixun, Chen, Kevin, Chiang, Chi-Lu, Chiu, Chao-Hua, Cicenas, Saulius, Ciubotaru, Elena, Ciuleanu, Tudor, Ciurescu, Ioana, Cobb, Patrick, Coetzee, Corlia, Collins, Dearbhaile, Cortinovis, Diego, Costas, Kimberly, Costin, Dan, Cronemberger, Eduardo Henrique, Cuevo, Raymund, Cuffe, Sinead, De Marchi, Pedro Rafael Martins, de Paiva Junior, Tadeu, Delmonte, Angelo, Demedts, Ingel, Deschepper, Koenraad, Dias, Josiane, Dooms, Christophe, Duchemann, Boris, Dutra, Carolina, Duvivier, Herbert, Eigendorff, Ekkehard, Ernani, Vinicius, Faehling, Martin, Faria, Luiza, Fedenko, Alexander, Fernando, Hiran, Ferrara, Roberto, Ferrari, Vittorio, Finley, Gene, Fix, Peter, Flores, Marcos, Fourie, Samuel, Franke, Fabio, Frohling, Klaus-Peter, Furqan, Muhammad, Gal, Cristian, Galamaga, Robert, Ganea, Doina, Ganti, Apar Kishor, Gao, Shugeng, Garassino, Marina, Gentzler, Ryan, Gianni, Luca, Gilli, Marina, Girard, Nicolas, Goranov, Bojidar, Gregorc, Vanesa, Greystoke, Alastair, Grisanti, Salvatore, Grohe, Christian, Guarino, Michael, Guimaraes, Jose Luiz, Guisier, Florian, Halmos, Balazs, Hammoud, Zane Taysir, Han, Ji-Youn, Hegmane, Alinta, Heng, Fook Yew, Horinouchi, Hidehito, Horio, Yoshitsugu, Hu, Jian, Huang, Hsu-Ching, Hui, Rina, Ikeda, Norihiko, Intagliata, Salvatore, Iordan, Ingrid, Jacobs, Conrad, Jain, Kirti, Jain, Sushil, Jiang, Tao, Karaseva, Nina, Kato, Terufumi, Kaywin, Paul, Kazmi, Shayma, Keresztes, Roger, Khan, Sarah, Kim, Jhingook, Kolesnik, Olena, Kolesnik, Oleksii, Kollmeier, Jens, Komiya, Takefumi, Koontz, Michael, Krasnohrud, Yuliia, Kristedja, Timothy, Kryzhanivska, Anna, Kuroda, Hiroaki, Laktionov, Konstantin, Lambrechts, Marc, Lang, Susanne, Langleben, Adrian, Lee, Se-Hoon, Lehmann, Markus, Levchenko, Evgeny, Levenko, Oleh, Li, Shanqing, Liao, Bin-Chi, Liberman, Moishe, Lima, Iane, Liu, Geoffrey, Liu-Dumlao, Theresa, Lo Russo, Giuseppe, Lou, Yan Yan, Lowczak, Anna, Luft, Alexander, Ma, Shaohua, Majem Tarruella, Margarita, Makles, Krytsyna, Martinengo, Gaston, Martinez Marti, Alex, Matias, Danielli, Mazieres, Julien, Mazilu, Laura, Mennecier, Bertrand, Migliorino, Maria Rita, Misleh, Jamal, Molina, Julian, Morbeck, Igor, Mueller, Annette, Muto, Satoshi, Nadal Alforja, Ernest, Nesterova, Alfiya, Nishio, Wataru, Niu, Jiaxin, Novello, Silvia, O'Brien, Mary, O'Day, Steven, Ogliari, Francesca, Okada, Morihito, Pang, Yong Kek, Paramonov, Viktor, Pastor, Andrea, Pawlak, Ireneusz, Piantedosi, Francovito, Pollock, Theodore, Pope, Tony, Puig, Juan, Radhi, Saba, Rao, Suman, Rathnasabapathy, Chenthilmurugan, Reck, Martin, Reinacher-Schick, Anke, Rich, Patricia, Ritgen, Mathias, Rittmeyer, Achim, Roca, Elisa, Rodriguez-Abreu, Delvys, Ruff, Paul, Rybkin, Igor, Saji, Hisashi, Sakao, Yukinori, Sangal, Ashish, Santoro, Armando, Sardenberg, Rodrigo, Savvides, Panayiotis, Scheusan, Roxana, Schiller, Joan, Schumacher, Lana, Serke, Monika, Shim, Byoung Yong, Shimizu, Junichi, Shio, Yutaka, Sibille, Anne, Siegel, Robert, Signorelli, Diego, Smagina, Maria, Sokur, Iryna, Spicer, Jonathan, Srkalovic, Gordan, Stampleman, Laura, Starodub, Alexander, Stencel, Katarzyna, Sugio, Kenji, Surmont, Veerle, Suzuki, Hiroyuki, Tabacof, Jacques, Takamochi, Kazuya, Tan, Lijie, Tanaka, Fumihiro, Tatangelo, Marcelo, Täuscher, Dagmar, Teixeira, Carlos, Thiberville, Luc, Trukhin, Dmytro, Tsai, Chen-Liang, Tsuboi, Masahiro, Ungureanu, Andrei, Ursol, Grygorii, Vanakesa, Tonu, Vansteenkiste, Johan, Varela, Mirta, Villalona-Calero, Miguel, Villaruz, Liza, Vogel, Gunther, Voitko, Nataliia, Wakelee, Heather, Wang, Qun, Wang, Wenxiang, Wang, Chin-Chou, Wang, Sarah, Wehler, Thomas, Weksler, Benny, Wermke, Martin, Wesseler, Claas, Wirtz, Hubert, Wong, Mark, Yan, Xiaolong, Yang, Yue, Yu, Kong Leong, Zasadny, Xavier, Zemaitis, Marius, Zhang, Lanjun, Zhao, Guofang, Zhao, Qing, Zhu, Yuming, Zurawski, Bogdan, Spicer, Jonathan D, Garassino, Marina C, Majem, Margarita, Martinengo, Gastón L, Rodríguez-Abreu, Delvys, Chaft, Jamie E, Yang, Jing, Arunachalam, Ashwini, Keller, Steven M, and Samkari, Ayman

Published
2024
Full Text
View/download PDF

2. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

Author

Mukherjee, Somnath, Morgan, Carys, Parsons, Simon L, Bhuva, Neel, Campbell, Sorcha, Grogan, Liam, Leonard, Greg, Bateman, Andrew R, Mitchell, Catherine, O'Reilly, Seamus, Mulroe, Eibhlin, McLoughlin, Olivia, Shevlin, Anna, Shannon, Aoife M, Marron, Jacinta, Nolan, Marc, Burch, Grace, Costello, Michelle, Griffiths, Daniel, Cozens, Kelly, Foley, Emma, Donohoe, Claire L, O'Farrell, Catherine, Moore, Jennifer, O'Sullivan, Jacintha, Reynolds, John V, Preston, Shaun R, O'Neill, Brian, Lowery, Maeve A, Baeksgaard, Lene, Crosby, Thomas, Cunningham, Moya, Cuffe, Sinead, Griffiths, Gareth O, Parker, Imelda, Risumlund, Signe Lenora, Roy, Rajarshi, Falk, Stephen, Hanna, George B, Bartlett, Frederick R, Alvarez-Iglesias, Alberto, Achiam, Michael P, Nilsson, Magnus, Piessen, Guillaume, Ravi, Narayanasamy, O'Toole, Dermot, Johnston, Ciaran, McDermott, Raymond S, Turkington, Richard C, Wahed, Shajahan, Sothi, Sharmila, Ford, Hugo, Wadley, Martin S, and Power, Derek

Published
2023
Full Text
View/download PDF

4. European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database

Author

Stahel, Rolf, Hiltbrunner, Anita, Kammler, Rosita, Marti, Nesa, Ruepp, Barbara, Dafni, Urania, Tsourti, Zoi, Zygoura, Panagiota, Vervita, Katerina, Dimopoulou, Georgia, Andriakopoulou, Charitini, Stavrou, Androniki, Rüschoff, Jan H., Haberecker, Martina, Dettwiler, Susanne, Prutek, Fabiola, Mittmann, Christiane, Opitz, Isabelle, Vrugt, Bart, Friess, Martina, Matter, Alessandra, Spichiger-Häusermann, Chloé, Kirschner, Michaela B., Felley-Bosco, Emanuela, Baas, Paul, Monkhorst, Kim, Nackaerts, Kristiaan, Verbeken, Eric, Weynand, Birgit, Nafteux, Philippe, Moons, Johnny, Peeters, Liesbet, Ampollini, Luca, Tiseo, Marcello, Silini, Enrico Maria, Gnetti, Letizia, Carbognani, Paolo, de Perrot, Marc, Bavaghar-Zaeimi, Fatemeh, Brcic, Luka, Samarzija, Miroslav, Seiwerth, Sven, Jakopovic, Marko, Nadal, Ernest, Cardenal, Felipe, Llatjos, Roger, Lorente, Susana, Syrigos, Konstantinos, Vamvakaris, Ioannis, Tsimpoukis, Sotirios, Boura, Paraskevi, Gray, Steven G., Finn, Stephen P., Nur, Mutaz Mohammed, Baird, Anne-Marie, Barr, Martin P., Cuffe, Sinead, Gately, Kathy, Aerts, Joachim, Thüsen, Jan von der, Bille, Andrea, Passani, Stefano, Brunelli, Alessandro, Curioni-Fontecedro, Alessandra, von der Thüsen, Jan, Kammler, Roswitha, Peters, Solange, Stahel, Rolf A., and Falcoz, Pierre-Emmanuel

Published
2023
Full Text
View/download PDF

5. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project

Author

Rüschoff, Jan Hendrik, Haberecker, Martina, Tsourti, Zoi, Nackaerts, Kristiaan, de Perrot, Marc, Brcic, Luka, Nadal, Ernest, Tsimpoukis, Sotirios, Gray, Steven G., Ampollini, Luca, Aerts, Joachim G., Felley-Bosco, Emanuela, Kirschner, Michaela B., Monkhorst, Kim, Weynand, Birgit, Bavaghar-Zaeimi, Fatemeh, Samarzija, Miroslav, Llatjos, Roger, Finn, Stephen P., Silini, Enrico, von der Thüsen, Jan, Marti, Nesa, Vervita, Karerina, Kammler, Roswitha, Peters, Solange, Stahel, Rolf A., Baas, Paul, Opitz, Isabelle, Stahel, Rolf, Hiltbrunner, Anita, Kammler, Rosita, Vagenknecht, Patrick, Ruepp, Barbara, Dafni, Urania, Zygoura, Panagiota, Vervita, Katerina, Dimopoulou, Georgia, Andriakopoulou, Charitini, Stavrou, Androniki, Rüschoff, Jan H., Dettwiler, Susanne, Prutek, Fabiola, Mittmann, Christiane, Vrugt, Bart, Friess, Martina, Matter, Alessandra, Spichiger-Häusermann, Chloé, Verbeken, Eric, Weyenand, Birgit, Peeters, Liesbet, Tiseo, Marcello, Silini, Enrico Maria, Ventura, Luigi, Gnetti, Letizia, Carbognani, Paolo, Zaeimi, Fatemeh B., Seiwerth, Sven, Jakopovic, Marko, Cardenal, Felipe, Lorente, Susana, Syrigos, Konstantinos, Vamvakaris, Ioannis, Boura, Paraskevi, Gray, Steven, Nur, Mutaz Mohammed, Baird, Anne-Marie, Barr, Martin, Cuffe, Sinead, Gately, Kathy, and Aerts, Joachim

Published
2022
Full Text
View/download PDF

6. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Author

Stahel, Rolf, Peters, Solange, Soo, Ross, Han, Ji-Youn, Früh, Martin, Provencio, Mariano, Coate, Linda, Dafni, Urania, Hiltbrunner, Anita, Ruepp, Barbara, Roschitzki-Voser, Heidi, Gasca-Ruchti, Adriana, Giacomelli, Nino, Kammler, Rosita, Marti, Nesa, Nobs, Lionel, Pardo-Contreras, Mariana, Pfister, Rita, Piguet, Anne-Christine, Ribeli-Hofmann, Sabrina, Martinez, Virginia Rodriguez, Roux, Susanne, Sanchez-Hohl, Magdalena, Schneider, Mirjam, Schweri, Robin, Troesch, Sandra, Zigomo, Isabel, Tsourti, Zoi, Zygoura, Panagiota, Kassapian, Marie, Vervita, Katerina, Dimopoulou, Georgia, Andriakopoulou, Charitini, Fernandez, Maria, Pereira, Eva, Simona, Carolina, Tucker, Lisa, Burnes, Jillian, Barrett, Aisling, McGrillen, Meghan, Berset, Catherine, Biaggi, Christine, Reist, Martin, Rentsch, Priska, Cuffe, Sinead, Hashemi, Sayed, Nadal, Ernest, Carcereny, Enric, de Castro, Javier, Sala, Maria Angeles, Reyes, Bernabé, Pulla, Mariano Provencio, Campelo, Rosario Garcia, Massutí, Bartomeu, Garcia, Jose, Dómine, Manuel, Majem, Margarita, Sanchez, Jose Miguel, Britschgi, Christian, Pless, Miklos, Yeo, Chong Ming, Cho, Byoung Chul, Soo, R.A., Han, J.-Y., Dafni, U., Cho, B.C., Yeo, C.M., Nadal, E., Carcereny, E., de Castro, J., Sala, M.A., Bernabé, R., Coate, L., Provencio Pulla, M., Garcia Campelo, R., Cuffe, S., Hashemi, S.M.S., Früh, M., Massuti, B., Garcia-Sanchez, J., Dómine, M., Majem, M., Sanchez-Torres, J.-M., Britschgi, C., Pless, M., Dimopoulou, G., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R.A., and Peters, S.

Published
2022
Full Text
View/download PDF

8. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Spicer, Jonathan D, Garassino, Marina C, Wakelee, Heather, Liberman, Moishe, Kato, Terufumi, Tsuboi, Masahiro, Lee, Se-Hoon, Chen, Ke-Neng, Dooms, Christophe, Majem, Margarita, Eigendorff, Ekkehard, Martinengo, Gastón L, Bylicki, Olivier, Rodríguez-Abreu, Delvys, Chaft, Jamie E, Novello, Silvia, Yang, Jing, Arunachalam, Ashwini, Keller, Steven M, Samkari, Ayman, Gao, Shugeng, Afanasyev, Sergey, Ahmed, Samreen, Alekshun, Todd, Alves, Gustavo, Anderson, Ian, Araujo, Luiz Henrique, Arkhipov, Alexander, Arora, Arvind, Bai, Jie, Begin, Paul, Belonogov, Aleksandr, Berard, Henri, Berceanu-Ion, Radu, Bernabe Caro, Reyes, Bondarenko, Igor, Bonnet, Reiner, Bosch Barrera, Joaquim, Brocca, Carlos, Bryl, Maciej, Bulotta, Alessandra, Bylicki, Olivier, Calles Blanco, Antonio, Carcereny, Enric, Carvalho, Leticia, Cebotaru, Cristina, Chaft, Jamie, Charu, Veena, Chaves, Fabio, Chen, Jun, Chen, Ke-Neng, Chen, Haiquan, Chen, Qixun, Chen, Kevin, Chiang, Chi-Lu, Chiu, Chao-Hua, Cicenas, Saulius, Ciubotaru, Elena, Ciuleanu, Tudor, Ciurescu, Ioana, Cobb, Patrick, Coetzee, Corlia, Collins, Dearbhaile, Cortinovis, Diego, Costas, Kimberly, Costin, Dan, Cronemberger, Eduardo Henrique, Cuevo, Raymund, Cuffe, Sinead, De Marchi, Pedro Rafael Martins, de Paiva Junior, Tadeu, Delmonte, Angelo, Demedts, Ingel, Deschepper, Koenraad, Dias, Josiane, Dooms, Christophe, Duchemann, Boris, Dutra, Carolina, Duvivier, Herbert, Eigendorff, Ekkehard, Ernani, Vinicius, Faehling, Martin, Faria, Luiza, Fedenko, Alexander, Fernando, Hiran, Ferrara, Roberto, Ferrari, Vittorio, Finley, Gene, Fix, Peter, Flores, Marcos, Fourie, Samuel, Franke, Fabio, Frohling, Klaus-Peter, Furqan, Muhammad, Gal, Cristian, Galamaga, Robert, Ganea, Doina, Ganti, Apar Kishor, Gao, Shugeng, Garassino, Marina, Gentzler, Ryan, Gianni, Luca, Gilli, Marina, Girard, Nicolas, Goranov, Bojidar, Gregorc, Vanesa, Greystoke, Alastair, Grisanti, Salvatore, Grohe, Christian, Guarino, Michael, Guimaraes, Jose Luiz, Guisier, Florian, Halmos, Balazs, Hammoud, Zane Taysir, Han, Ji-Youn, Hegmane, Alinta, Heng, Fook Yew, Horinouchi, Hidehito, Horio, Yoshitsugu, Hu, Jian, Huang, Hsu-Ching, Hui, Rina, Ikeda, Norihiko, Intagliata, Salvatore, Iordan, Ingrid, Jacobs, Conrad, Jain, Kirti, Jain, Sushil, Jiang, Tao, Karaseva, Nina, Kato, Terufumi, Kaywin, Paul, Kazmi, Shayma, Keresztes, Roger, Khan, Sarah, Kim, Jhingook, Kolesnik, Olena, Kolesnik, Oleksii, Kollmeier, Jens, Komiya, Takefumi, Koontz, Michael, Krasnohrud, Yuliia, Kristedja, Timothy, Kryzhanivska, Anna, Kuroda, Hiroaki, Laktionov, Konstantin, Lambrechts, Marc, Lang, Susanne, Langleben, Adrian, Lee, Se-Hoon, Lehmann, Markus, Levchenko, Evgeny, Levenko, Oleh, Li, Shanqing, Liao, Bin-Chi, Liberman, Moishe, Lima, Iane, Liu, Geoffrey, Liu-Dumlao, Theresa, Lo Russo, Giuseppe, Lou, Yan Yan, Lowczak, Anna, Luft, Alexander, Ma, Shaohua, Majem Tarruella, Margarita, Makles, Krytsyna, Martinengo, Gaston, Martinez Marti, Alex, Matias, Danielli, Mazieres, Julien, Mazilu, Laura, Mennecier, Bertrand, Migliorino, Maria Rita, Misleh, Jamal, Molina, Julian, Morbeck, Igor, Mueller, Annette, Muto, Satoshi, Nadal Alforja, Ernest, Nesterova, Alfiya, Nishio, Wataru, Niu, Jiaxin, Novello, Silvia, O'Brien, Mary, O'Day, Steven, Ogliari, Francesca, Okada, Morihito, Pang, Yong Kek, Paramonov, Viktor, Pastor, Andrea, Pawlak, Ireneusz, Piantedosi, Francovito, Pollock, Theodore, Pope, Tony, Puig, Juan, Radhi, Saba, Rao, Suman, Rathnasabapathy, Chenthilmurugan, Reck, Martin, Reinacher-Schick, Anke, Rich, Patricia, Ritgen, Mathias, Rittmeyer, Achim, Roca, Elisa, Rodriguez-Abreu, Delvys, Ruff, Paul, Rybkin, Igor, Saji, Hisashi, Sakao, Yukinori, Sangal, Ashish, Santoro, Armando, Sardenberg, Rodrigo, Savvides, Panayiotis, Scheusan, Roxana, Schiller, Joan, Schumacher, Lana, Serke, Monika, Shim, Byoung Yong, Shimizu, Junichi, Shio, Yutaka, Sibille, Anne, Siegel, Robert, Signorelli, Diego, Smagina, Maria, Sokur, Iryna, Spicer, Jonathan, Srkalovic, Gordan, Stampleman, Laura, Starodub, Alexander, Stencel, Katarzyna, Sugio, Kenji, Surmont, Veerle, Suzuki, Hiroyuki, Tabacof, Jacques, Takamochi, Kazuya, Tan, Lijie, Tanaka, Fumihiro, Tatangelo, Marcelo, Täuscher, Dagmar, Teixeira, Carlos, Thiberville, Luc, Trukhin, Dmytro, Tsai, Chen-Liang, Tsuboi, Masahiro, Ungureanu, Andrei, Ursol, Grygorii, Vanakesa, Tonu, Vansteenkiste, Johan, Varela, Mirta, Villalona-Calero, Miguel, Villaruz, Liza, Vogel, Gunther, Voitko, Nataliia, Wakelee, Heather, Wang, Qun, Wang, Wenxiang, Wang, Chin-Chou, Wang, Sarah, Wehler, Thomas, Weksler, Benny, Wermke, Martin, Wesseler, Claas, Wirtz, Hubert, Wong, Mark, Yan, Xiaolong, Yang, Yue, Yu, Kong Leong, Zasadny, Xavier, Zemaitis, Marius, Zhang, Lanjun, Zhao, Guofang, Zhao, Qing, Zhu, Yuming, and Zurawski, Bogdan

Abstract

At the first interim analysis of the KEYNOTE-671 trial, adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved event-free survival in participants with early-stage non-small-cell lung cancer (NSCLC). We report overall survival and health-related quality of life outcomes from the second interim analysis.

Published
2024
Full Text
View/download PDF

9. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

Author

Reynolds, John V, primary, Preston, Shaun R, additional, O'Neill, Brian, additional, Lowery, Maeve A, additional, Baeksgaard, Lene, additional, Crosby, Thomas, additional, Cunningham, Moya, additional, Cuffe, Sinead, additional, Griffiths, Gareth O, additional, Parker, Imelda, additional, Risumlund, Signe Lenora, additional, Roy, Rajarshi, additional, Falk, Stephen, additional, Hanna, George B, additional, Bartlett, Frederick R, additional, Alvarez-Iglesias, Alberto, additional, Achiam, Michael P, additional, Nilsson, Magnus, additional, Piessen, Guillaume, additional, Ravi, Narayanasamy, additional, O'Toole, Dermot, additional, Johnston, Ciaran, additional, McDermott, Raymond S, additional, Turkington, Richard C, additional, Wahed, Shajahan, additional, Sothi, Sharmila, additional, Ford, Hugo, additional, Wadley, Martin S, additional, Power, Derek, additional, Mukherjee, Somnath, additional, Morgan, Carys, additional, Parsons, Simon L, additional, Bhuva, Neel, additional, Campbell, Sorcha, additional, Grogan, Liam, additional, Leonard, Greg, additional, Bateman, Andrew R, additional, Mitchell, Catherine, additional, O'Reilly, Seamus, additional, Mulroe, Eibhlin, additional, McLoughlin, Olivia, additional, Shevlin, Anna, additional, Shannon, Aoife M, additional, Marron, Jacinta, additional, Nolan, Marc, additional, Burch, Grace, additional, Costello, Michelle, additional, Griffiths, Daniel, additional, Cozens, Kelly, additional, Foley, Emma, additional, Donohoe, Claire L, additional, O'Farrell, Catherine, additional, Moore, Jennifer, additional, and O'Sullivan, Jacintha, additional

Published
2023
Full Text
View/download PDF

10. An Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC)

Author

Murphy, Ciara, primary, Gornés Pons, Glòria, additional, Keogh, Anna, additional, Ryan, Lisa, additional, McCarra, Lorraine, additional, Jose, Chris Maria, additional, Kesar, Shagun, additional, Nicholson, Siobhan, additional, Fitzmaurice, Gerard J., additional, Ryan, Ronan, additional, Young, Vincent, additional, Cuffe, Sinead, additional, Finn, Stephen P., additional, and Gray, Steven G., additional

Published
2023
Full Text
View/download PDF

11. European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database

Author

Opitz, Isabelle, primary, Bille, Andrea, additional, Dafni, Urania, additional, Nackaerts, Kristiaan, additional, Ampollini, Luca, additional, de Perrot, Marc, additional, Brcic, Luka, additional, Nadal, Ernest, additional, Syrigos, Konstantinos, additional, Gray, Steven G., additional, Aerts, Joachim, additional, Curioni-Fontecedro, Alessandra, additional, Rüschoff, Jan H., additional, Monkhorst, Kim, additional, Weynand, Birgit, additional, Silini, Enrico Maria, additional, Bavaghar-Zaeimi, Fatemeh, additional, Jakopovic, Marko, additional, Llatjos, Roger, additional, Tsimpoukis, Sotirios, additional, Finn, Stephen P., additional, von der Thüsen, Jan, additional, Marti, Nesa, additional, Dimopoulou, Georgia, additional, Kammler, Roswitha, additional, Peters, Solange, additional, Stahel, Rolf A., additional, Falcoz, Pierre-Emmanuel, additional, Brunelli, Alessandro, additional, Baas, Paul, additional, Stahel, Rolf, additional, Hiltbrunner, Anita, additional, Kammler, Rosita, additional, Ruepp, Barbara, additional, Tsourti, Zoi, additional, Zygoura, Panagiota, additional, Vervita, Katerina, additional, Andriakopoulou, Charitini, additional, Stavrou, Androniki, additional, Haberecker, Martina, additional, Dettwiler, Susanne, additional, Prutek, Fabiola, additional, Mittmann, Christiane, additional, Opitz, Isabelle, additional, Vrugt, Bart, additional, Friess, Martina, additional, Matter, Alessandra, additional, Spichiger-Häusermann, Chloé, additional, Kirschner, Michaela B., additional, Felley-Bosco, Emanuela, additional, Verbeken, Eric, additional, Nafteux, Philippe, additional, Moons, Johnny, additional, Peeters, Liesbet, additional, Tiseo, Marcello, additional, Gnetti, Letizia, additional, Carbognani, Paolo, additional, Samarzija, Miroslav, additional, Seiwerth, Sven, additional, Cardenal, Felipe, additional, Lorente, Susana, additional, Vamvakaris, Ioannis, additional, Boura, Paraskevi, additional, Nur, Mutaz Mohammed, additional, Baird, Anne-Marie, additional, Barr, Martin P., additional, Cuffe, Sinead, additional, Gately, Kathy, additional, Thüsen, Jan von der, additional, and Passani, Stefano, additional

Published
2023
Full Text
View/download PDF

12. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS):an open-label, randomised, phase 3 trial

Author

Reynolds, John V., Preston, Shaun R., O'Neill, Brian, Lowery, Maeve A., Baeksgaard, Lene, Crosby, Thomas, Cunningham, Moya, Cuffe, Sinead, Griffiths, Gareth O., Parker, Imelda, Risumlund, Signe Lenora, Roy, Rajarshi, Falk, Stephen, Hanna, George B., Bartlett, Frederick R., Alvarez-Iglesias, Alberto, Achiam, Michael P., Nilsson, Magnus, Piessen, Guillaume, Ravi, Narayanasamy, O'Toole, Dermot, Johnston, Ciaran, McDermott, Raymond S., Turkington, Richard C., Wahed, Shajahan, Sothi, Sharmila, Ford, Hugo, Wadley, Martin S., Power, Derek, Reynolds, John V., Preston, Shaun R., O'Neill, Brian, Lowery, Maeve A., Baeksgaard, Lene, Crosby, Thomas, Cunningham, Moya, Cuffe, Sinead, Griffiths, Gareth O., Parker, Imelda, Risumlund, Signe Lenora, Roy, Rajarshi, Falk, Stephen, Hanna, George B., Bartlett, Frederick R., Alvarez-Iglesias, Alberto, Achiam, Michael P., Nilsson, Magnus, Piessen, Guillaume, Ravi, Narayanasamy, O'Toole, Dermot, Johnston, Ciaran, McDermott, Raymond S., Turkington, Richard C., Wahed, Shajahan, Sothi, Sharmila, Ford, Hugo, Wadley, Martin S., and Power, Derek

Abstract

Background: The optimum curative approach to adenocarcinoma of the oesophagus and oesophagogastric junction is unknown. We aimed to compare trimodality therapy (preoperative radiotherapy with carboplatin plus paclitaxel [CROSS regimen]) with optimum contemporaneous perioperative chemotherapy regimens (epirubicin plus cisplatin or oxaliplatin plus fluorouracil or capecitabine [a modified MAGIC regimen] before 2018 and fluorouracil, leucovorin, oxaliplatin, and docetaxel [FLOT] subsequently). Methods: Neo-AEGIS (CTRIAL-IE 10-14) was an open-label, randomised, phase 3 trial done at 24 centres in Europe. Patients aged 18 years or older with clinical tumour stage T2–3, nodal stage N0–3, and M0 adenocarcinoma of the oesophagus and oesophagogastric junction were randomly assigned to perioperative chemotherapy (three preoperative and three postoperative 3-week cycles of intravenous 50 mg/m2 epirubicin on day 1 plus intravenous 60 mg/m2 cisplatin or intravenous 130 mg/m2 oxaliplatin on day 1 plus continuous infusion of 200 mg/m2 fluorouracil daily or oral 625 mg/m2 capecitabine twice daily up to 2018, with four preoperative and four postoperative 2-week cycles of 2600 mg/m2 fluorouracil, 85 mg/m2 oxaliplatin, 200 mg/m2 leucovorin, and 50 mg/m2 docetaxel intravenously on day 1 as an option from 2018) or trimodality therapy (41·4 Gy in 23 fractions on days 1−5, 8−12, 15–19, 22–26, and 29–31 with intravenous area under the curve 2 mg/mL per min carboplatin plus intravenous 50 mg/m2 paclitaxel on days 1, 8, 15, 22, and 29). The primary endpoint was overall survival, assessed in all randomly assigned patients who received at least one dose of study drug, regardless of which study drug they received, by intention to treat. Secondary endpoints were disease-free survival, site of treatment failure, operative complications, toxicity, pathological response (complete [ypT0N0

Published
2023

13. Feasibility Randomised Control Trial of OptiMal: A Self-Management Intervention for Cancer Survivors.

Author

Boland, Lauren, Bennett, Kathleen E., Cuffe, Sinead, Grant, Cliona, Kennedy, M. John, and Connolly, Deirdre

Subjects
CANCER fatigue, CANCER survivors, QUALITY of life, PHYSIOLOGICAL stress, INFERENTIAL statistics, FEASIBILITY studies
Abstract

Purpose: Cancer survivors can experience symptoms such as fatigue, pain and distress that persist for many months following treatment. These enduring symptoms often impact on participation in self-care activities, returning to school and/or work, and leisure and social activities. Self-management support is increasingly recognised as a core aspect of cancer survivorship care to reduce the impact of persistent symptoms. The purpose of this study was to examine the feasibility and potential effectiveness of a group-based self-management intervention, OptiMal, to improve the physical and psychological health of cancer survivors. OptiMal is a six-week intervention comprising weekly sessions on fatigue, stress and physical activity, diet and effective communication strategies. Methods: A feasibility randomised control trial was undertaken. Individuals up to two years after cancer treatment were randomised to OptiMal or usual care. Feasibility was examined through recruitment and retention metrics. Potential effectiveness was tested through patient-reported outcomes collected at baseline and three months post-intervention. Descriptive and inferential statistics were used to analyse study data. Results: Recruitment for this study was 32.5% (80/246 eligible individuals) with 77.5% retention at three-month follow-up (82.5% for intervention group and 72.5% for control group). Of those who attended the intervention, 19 (73%) attended all OptiMal sessions, indicating high adherence to the intervention. The majority of participants had breast cancer and were between 12 and 24 months post-treatment. The intervention group (n = 29) had statistically significant greater improvements in anxiety (p = 0.04) and health-related quality of life (health index score: p = 0.023, visual analogue score: p = 0.035) at three months post-intervention than the control group. Conclusions: Recruitment and retention in this study was similar to other cancer trials and the high adherence rate indicates that OptiMal is an acceptable self-management intervention for cancer survivors and warrants further investigation. OptiMal is intended to address symptoms reported across different cancer types. However, a limitation of this study was that the majority of participants had breast cancer, and therefore, generalisability of findings cannot be assumed for other cancer types. Future studies of OptiMal therefore need to use different strategies to recruit survivors of other cancer types. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Supplementary Table 1 from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

Author

Liu, Geoffrey, primary, Cuffe, Sinead, primary, Liang, Shermi, primary, Azad, Abul Kalam, primary, Cheng, Lu, primary, Brhane, Yonathan, primary, Qiu, Xin, primary, Cescon, David W., primary, Bruce, Jeffrey, primary, Chen, Zhuo, primary, Cheng, Dangxiao, primary, Patel, Devalben, primary, Tse, Brandon C., primary, Laurie, Scott A., primary, Goss, Glenwood, primary, Leighl, Natasha B., primary, Hung, Rayjean, primary, Bradbury, Penelope A., primary, Seymour, Lesley, primary, Shepherd, Frances A., primary, Tsao, Ming Sound, primary, Chen, Bingshu E., primary, Xu, Wei, primary, and Reisman, David N., primary

Published
2023
Full Text
View/download PDF

15. Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis.

Author

Reynolds, John V., primary, Preston, Shaun R., additional, O'Neill, Brian, additional, Lowery, Maeve Aine, additional, Baeksgaard, Lene, additional, Crosby, Thomas, additional, Cunningham, Moya, additional, Cuffe, Sinead, additional, Griffiths, Gareth Owen, additional, Roy, Rajarshi, additional, Falk, Stephen, additional, Hanna, George, additional, Bartlett, Frederick R., additional, Parker, Imelda, additional, Alvarez-Iglesias, Alberto, additional, Nilsson, Magnus, additional, Piessen, Guillaume, additional, Risum, Signe, additional, Ravi, Narayanasamy, additional, and McDermott, Raymond S., additional

Published
2023
Full Text
View/download PDF

16. Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial

Author

Felip, Enriqueta, primary, Smit, Egbert F., additional, Molina-Vila, Miguel A., additional, Dafni, Urania, additional, Massuti, Bartomeu, additional, Berghmans, Thierry, additional, de Marinis, Filippo, additional, Passiglia, Francesco, additional, Dingemans, Anne-Marie C., additional, Cobo, Manuel, additional, Viteri, Santiago, additional, Britschgi, Christian, additional, Cuffe, Sinead, additional, Provencio, Mariano, additional, Merkelbach-Bruse, Sabine, additional, Andriakopoulou, Charitini, additional, Kammler, Roswitha, additional, Ruepp, Barbara, additional, Roschitzki-Voser, Heidi, additional, Peters, Solange, additional, Wolf, Jürgen, additional, and Stahel, Rolf, additional

Published
2022
Full Text
View/download PDF

17. Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC

Author

Barr, Martin P., primary, Baird, Anne-Marie, additional, Halliday, Sophia, additional, Martin, Petra, additional, Allott, Emma H., additional, Phelan, James, additional, Korpanty, Greg, additional, Coate, Linda, additional, O’Brien, Cathal, additional, Gray, Steven G., additional, Sui, Jane S. Y., additional, Hayes, Brian, additional, Cuffe, Sinead, additional, and Finn, Stephen P., additional

Published
2022
Full Text
View/download PDF

18. Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial

Author

Felip, Enriqueta, Smit, Egbert F., Molina-Vila, Miguel A., Dafni, Urania, Massuti, Bartomeu, Berghmans, Thierry, de Marinis, Filippo, Passiglia, Francesco, Dingemans, Anne-Marie C., Cobo, Manuel, Viteri, Santiago, Britschgi, Christian, Cuffe, Sinead, Provencio, Mariano, Merkelbach-Bruse, Sabine, Andriakopoulou, Charitini, Kammler, Roswitha, Ruepp, Barbara, Roschitzki-Voser, Heidi, Peters, Solange, Wolf, Juergen, Stahel, Rolf, Felip, Enriqueta, Smit, Egbert F., Molina-Vila, Miguel A., Dafni, Urania, Massuti, Bartomeu, Berghmans, Thierry, de Marinis, Filippo, Passiglia, Francesco, Dingemans, Anne-Marie C., Cobo, Manuel, Viteri, Santiago, Britschgi, Christian, Cuffe, Sinead, Provencio, Mariano, Merkelbach-Bruse, Sabine, Andriakopoulou, Charitini, Kammler, Roswitha, Ruepp, Barbara, Roschitzki-Voser, Heidi, Peters, Solange, Wolf, Juergen, and Stahel, Rolf

Abstract

Background: Alectinib, a highly selective next generation ALK-inhibitor, has exhibited potent anti-tumour activity in RET-rearranged NSCLC in the preclinical stage. Methods: ALERT-lung is a single-arm, phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC. Alectinib was administered orally, 600 mg, twice per day until progression, refusal or unacceptable toxicity (treatment could continue beyond progression, if patient was deriving clinical benefit). Patient recruitment closed prematurely due to discouraging results for alectinib in a phase I/II study in the same indication. Results: All 14 patients who enrolled until the premature accrual closure, received at lease one dose of alectinib. Among them, median age was 61 years, majority (71 %) was female, never smokers, of ECOG PS 1. No objective response (complete or partial response) was recorded. Of the 13 evaluable patients, three (23 %) achieved and maintained disease stabilisation for 24 weeks. Up to 31 March 2021 (median follow-up 15.9 months), 12 PFS-events (92 %) were observed, with median PFS of 3.7 months (95 % C.I.: 1.8 - 7.3 months). Overall, three deaths (23 %) were reported. Seven patients (50 %) experienced grade = 3 adverse events, while three discontinued treatment due to erythema multiforme of grade 3, related to alectinib. No treatment-related serious adverse event was reported. Conclusions: Accrual into our trial was terminated early in response to other reports of limited activity of alectinib in patients with RET-fusion NSCLC and the emergence of more potent selective RET-inhibitors. Also in our trial, alectinib did not show the expected potential for anti-tumour activity in NSCLC.

Published
2022

19. Patient knowledge, personal experience, and impact of the first wave of the COVD-19 pandemic in an Irish oncology cohort

Author

Kieran, Ruth, primary, Moloney, Carolyn, additional, Alken, Scheryll, additional, Corrigan, Lynda, additional, Gallagher, David, additional, Grant, Cliona, additional, Kelleher, Fergal, additional, Kennedy, M. John, additional, Lowery, Maeve A., additional, McCarthy, Michael, additional, O’Donnell, Dearbhaile M., additional, Sukor, Sue, additional, and Cuffe, Sinead, additional

Published
2022
Full Text
View/download PDF

20. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Author

Soo, R.A., primary, Han, J.-Y., additional, Dafni, U., additional, Cho, B.C., additional, Yeo, C.M., additional, Nadal, E., additional, Carcereny, E., additional, de Castro, J., additional, Sala, M.A., additional, Bernabé, R., additional, Coate, L., additional, Provencio Pulla, M., additional, Garcia Campelo, R., additional, Cuffe, S., additional, Hashemi, S.M.S., additional, Früh, M., additional, Massuti, B., additional, Garcia-Sanchez, J., additional, Dómine, M., additional, Majem, M., additional, Sanchez-Torres, J.-M., additional, Britschgi, C., additional, Pless, M., additional, Dimopoulou, G., additional, Roschitzki-Voser, H., additional, Ruepp, B., additional, Rosell, R., additional, Stahel, R.A., additional, Peters, S., additional, Stahel, Rolf, additional, Peters, Solange, additional, Soo, Ross, additional, Han, Ji-Youn, additional, Früh, Martin, additional, Provencio, Mariano, additional, Coate, Linda, additional, Dafni, Urania, additional, Hiltbrunner, Anita, additional, Ruepp, Barbara, additional, Roschitzki-Voser, Heidi, additional, Gasca-Ruchti, Adriana, additional, Giacomelli, Nino, additional, Kammler, Rosita, additional, Marti, Nesa, additional, Nobs, Lionel, additional, Pardo-Contreras, Mariana, additional, Pfister, Rita, additional, Piguet, Anne-Christine, additional, Ribeli-Hofmann, Sabrina, additional, Martinez, Virginia Rodriguez, additional, Roux, Susanne, additional, Sanchez-Hohl, Magdalena, additional, Schneider, Mirjam, additional, Schweri, Robin, additional, Troesch, Sandra, additional, Zigomo, Isabel, additional, Tsourti, Zoi, additional, Zygoura, Panagiota, additional, Kassapian, Marie, additional, Vervita, Katerina, additional, Dimopoulou, Georgia, additional, Andriakopoulou, Charitini, additional, Fernandez, Maria, additional, Pereira, Eva, additional, Simona, Carolina, additional, Tucker, Lisa, additional, Burnes, Jillian, additional, Barrett, Aisling, additional, McGrillen, Meghan, additional, Berset, Catherine, additional, Biaggi, Christine, additional, Reist, Martin, additional, Rentsch, Priska, additional, Cuffe, Sinead, additional, Hashemi, Sayed, additional, Nadal, Ernest, additional, Carcereny, Enric, additional, de Castro, Javier, additional, Sala, Maria Angeles, additional, Reyes, Bernabé, additional, Pulla, Mariano Provencio, additional, Campelo, Rosario Garcia, additional, Massutí, Bartomeu, additional, Garcia, Jose, additional, Dómine, Manuel, additional, Majem, Margarita, additional, Sanchez, Jose Miguel, additional, Britschgi, Christian, additional, Pless, Miklos, additional, Yeo, Chong Ming, additional, and Cho, Byoung Chul, additional

Published
2022
Full Text
View/download PDF

21. Additional file 1 of Altered expression of ACOX2 in non-small cell lung cancer

Author

Sui, Jane S. Y., Martin, Petra, Keogh, Anna, Murchan, Pierre, Ryan, Lisa, Nicholson, Siobhan, Cuffe, Sinead, Broin, Pilib Ó, Finn, Stephen P., Fitzmaurice, Gerard J., Ryan, Ronan, Young, Vincent, and Gray, Steven G.

Abstract

Additional file 1. Analysis of TCGA-LUAD and –LUSC datasets for alterations in acyl-CoA peroxidases at the mRNA and protein level.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results